Bridging of oral anticoagulation with low-molecular-weight heparin: Experience in 373 patients with renal insufficiency undergoing invasive procedures

Thrombosis and Haemostasis

Volumn 101, Issue 6, 2009, Pages 1085-1090

  Hammerstingl, Christoph ^a   Omran, Heyder ^a  

^a ST MARIEN HOSPITAL   (Germany)

Author keywords

Anticoagulation; Bleeding; Bridging; Enoxaparin; Low molecular weight heparin; Perioperative management; Register; Stratification; Surgery; Thrombosis

Indexed keywords

ENOXAPARIN; PHENPROCOUMON; ANTICOAGULANT AGENT; CREATININE;

ADULT; ANTICOAGULATION; ARTICLE; CHRONIC KIDNEY FAILURE; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; ILIOPSOAS HEMATOMA; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; LOW DRUG DOSE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; THROMBOEMBOLISM; AGED; CHEMICALLY INDUCED; COMPLICATION; DOSE CALCULATION; FEMALE; HEMORRHAGE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENAL INSUFFICIENCY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CREATININE; DRUG DOSAGE CALCULATIONS; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; MALE; PERIOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY; RISK FACTORS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 67049117569     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-01-0039     Document Type: Article

References (31)

1. Spyropoulos AC. Bridging of oral anticoagulation therapy for invasive procedures. Curr Hematol Rep 2005; 4: 405-413.
2. Coresh J, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12. (Pubitemid 36043346)
3. Elsayed EF, et al. Cardiovascular Disease and Subsequent Kidney Disease. Arch Intern Med 2007; 167: 1130-1136. (Pubitemid 46919815)
4. Freedman BI, DuBose TD, Jr. Chronic kidney disease: Cause and consequence of cardiovascular disease. Arch Intern Med 2007; 167: 1113-1115.
5. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Updated 2002. Available at: http://www.kidney.org/profes sionals/kdoqi/guidelines-ckd/ toc.htm. Accessed on 26. September 2008.
6. Douketis JD, et al. The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.). Chest 2008; 133: 299S-339. (Pubitemid 351894915)
7. Lim W, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-684. (Pubitemid 46780653)
8. Spyropoulos AC, et al. Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr Med Res Opin 2006; 22: 1109-1122.
9. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004; 148: 582-589. (Pubitemid 39349375)
10. Collet JP, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001; 80: 81-82. (Pubitemid 32800808)
11. Omran H, et al. Perioperative bridging with enoxaparin. Results of the prospective BRAVE registry with 779 patients. Med Klin (Munich) 2007; 102: 809-815.
12. Hammerstingl C, et al. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 2007; 16: 285-292. (Pubitemid 46887057)
13. Singer DE, et al. Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.). Chest 2008; 133: 546S-592.
14. Singer DE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 429S-456S.
15. Jovanovic BD, Zalenski RJ. Safety evaluation and confidence intervals when the number of observed events is small or zero. Ann Emerg Med 1997; 30: 301-306. (Pubitemid 27371871)
16. Gage BF, et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864. (Pubitemid 32537350)
17. Hirsh J, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Ed.). Chest 2008; 133: 110S-112S. (Pubitemid 351892962)
18. Hirsh J, et al. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.). Chest 2008; 133: 141S-159. (Pubitemid 351892966)
19. Spyropoulos AC, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 4: 1246-1252. (Pubitemid 43756701)
20. Mahe I, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007; 97: 581-586. (Pubitemid 46592936)
21. Hammerstingl C, et al. How useful is determination of anti factor Xa activity to guide bridging therapy with enoxaparin? A Pilot Study. Thromb Haemost 2009; 101: 325-332.
22. Ma JM, et al. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease. Ann Pharmacother 2004; 38: 1576-1581. (Pubitemid 39297749)
23. Berges A, et al. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007; 64: 428-438. (Pubitemid 47404307)
24. Green B, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005; 59: 281-290. (Pubitemid 40388082)
25. Hulot JS, et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542-552. (Pubitemid 40824967)
26. Sanderink GJ, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-231. (Pubitemid 34260945)
27. Schuck O, et al. Predicting the glomerular filtration rate from serum creatinine, serum cystatin C and the Cockcroft and Gault formula with regard to drug dosage adjustment. Int J Clin Pharmacol Ther 2004; 42: 93-97. (Pubitemid 38219920)
28. Bazinet A, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005; 116: 41-50. (Pubitemid 40546324)
29. Bick RL, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thromb Hemost 1999; 5 (Suppl 1): S63-6. (Pubitemid 29529683)
30. Ofosu FA. Differences in the safety profiles of two low-molecular-weight heparins. Thromb Haemost 2008; 99: 989-990. (Pubitemid 351810476)
31. Omran H, et al. A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization. Thromb Haemost 2003; 90: 267-271. (Pubitemid 36992503)